CYCC Cyclacel Pharmaceuticals Inc.

0.37
-0.02  -6%
Previous Close 0.4
Open 0.37
Price To Book 0.41
Market Cap 6,400,110
Shares 17,199,974
Volume 31,734
Short Ratio
Av. Daily Volume 57,749
Stock charts supplied by TradingView

NewsSee all news

  1. Cyclacel Pharmaceuticals to Release Third Quarter 2019 Financial Results

    BERKELEY HEIGHTS, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative

  2. Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting

    BERKELEY HEIGHTS, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative

  3. Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    BERKELEY HEIGHTS, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative

  4. Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors

    BERKELEY HEIGHTS, N.J., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative

  5. Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference

    BERKELEY HEIGHTS, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Noted mid-Dec 2014 that interim analysis suggests that trial will fail. Top-line data released February 23, 2017 that primary endpoint was not met. Complete remission (CR) improvement noted - secondary endpoint.
Sapacitabine (SEAMLESS)
Acute myeloid leukemia - cancer
Phase 1 (Part 2/3) data due 2020.
CYC065
Advanced cancers
Phase 1 initial data due at ASH December 7, 2019 at 5:30 PM ET.
CYC065 + venetoclax
Chronic lymphocytic leukemia (CLL)
Phase 1b/2 initial data due 2019.
Sapacitabine in combination with olaparib
BRCA mutant breast cancer
Phase 1 initial data due 2019.
CYC140
Leukemias
Phase 1 data at AACR April 1, 2019. 2/20 partial responses (PRs).
Sapacitabine and seliciclib
BRCA mutant breast cancer
Phase 1/2 trial dosing has commenced - July 22, 2019.
Sapacitabine and Venetoclax
Relapsed or refractory Acute myeloid leukemia or myelodysplastic syndrome (MDS)

Latest News

  1. Cyclacel Pharmaceuticals to Release Third Quarter 2019 Financial Results

    BERKELEY HEIGHTS, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative

  2. Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting

    BERKELEY HEIGHTS, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative

  3. Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    BERKELEY HEIGHTS, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative

  4. Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors

    BERKELEY HEIGHTS, N.J., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative

  5. Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference

    BERKELEY HEIGHTS, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative